Study Shows Clinicians Hesitant to Prescribe Newer, More Effective Antibiotics to Treat Gram-Negative Infections
A study undertaken by researchers at the National Institutes of Health’s Clinical Center suggests that “clinicians frequently continue to treat antibiotic-resistant infections with older generic antibiotics considered to be less effective and less safe” than newly approved alternatives. NIH’s website published a press release regarding the study on April 19.
Seven next-generation antibiotics have been approved by the FDA for use in fighting “infections caused by resistant ‘gram-negative’ bacteria,” but many clinicians seem to have a preference for the older traditional generic antibiotics when it comes time to prescribe.
Researchers uncovered that “smaller facilities located in rural areas” were particularly reluctant to adopt newer antibiotics, in part because of a “large cost disparity between older and newer classes of antibiotics; the newer drugs can cost approximately six times more than the older medications.” They also highlight that “next-gen agents are prescribed more often at hospitals where lab results that show the medications are effective against a patient’s bacterial infection are reported to prescribers.”
Gram-negative bacteria are particularly difficult to treat because they are “resistant to multiple drugs and increasingly resistant to most antibiotics.”
About the Author
Matt MacKenzieMatt MacKenzie
Associate Editor
Matt MacKenzie is Senior Staff Writer and Associate Editor of Healthcare Purchasing News (HPN), where he leads daily news coverage and contributes in-depth features on healthcare supply chain, sterile processing, infection prevention and clinical operations. Through industry reporting and expert interviews, he examines the trends, technologies and operational challenges shaping healthcare purchasing and patient care.


